drugset / Trial / NCT00368394

Dose-Exposure-Response in Type 1 Diabetes Mellitus

NCT00368394

Phase 1 Completed 18 enrolled Sanofi
RandomizedCrossoverSingle-blindTreatment

Summary

To investigate the dose-exposure-response relationship of insulin glulisine (HMR1964) after single subcutaneous injections of 0.075, 0.15 and 0.3 U/kg body weight with the euglycaemic clamp technique using the Biostator (TM).

Timeline

Start
2004-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Insulin glulisine Protein / enzyme biologic 0.075 unknown Subcutaneous
Subject Insulin glulisine Protein / enzyme biologic 0.15 unknown Subcutaneous
Subject Insulin glulisine Protein / enzyme biologic 0.3 unknown Subcutaneous